Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)

Conditions

Diseases of the Musculoskeletal System

Phase III

Volunteers
Health Professionals

What is the purpose of this trial?

Brief Summary:

To evaluate the safety and tolerability of FG-3019 in subjects with IPF, and the efficacy of FG-3019 in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these subjects.

Ages
40 years - 80 years
Gender
Both

Find out more about who can participate in this trial

Trial with
Ra Pharmaceuticals, Inc.
Start Date
07/01/2020
End Date
12/31/2020

For more information about this study, contact:

Bailey Munro Sheldon

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Richard Nowak, MD, MS
Assistant Professor of Neurology; Director, Program in Clinical & Translational Neuromuscular Research; Director, Yale Myasthenia Gravis Clinic

Sub-Investigator

Bhaskar Roy, MBBS, MBioMedSci, MHS

Last Updated
07/15/2021
Study HIC
#2000026786

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigator

Contact Information